Vericel (VCEL)

Executive Summary

Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced autologous cell therapies for sports medicine and severe burn care, with FDA-approved products MACI (knee cartilage repair), Epicel (severe burns), and the licensed NexoBrid (enzymatic debridement). The company generates revenue from these marketed products, but its pipeline is notably thin, with no active clinical trials listed. The completed trials for Ixmyelocel-T and other cell therapies in critical limb ischemia, dilated cardiomyopathy, and bone repair have not progressed to commercialization. Vericel's near-term growth depends on label expansions for MACI (e.g., hip, ankle) and NexoBrid (e.g., pediatric use), as well as increased market penetration. Financial performance has been steady, but lack of pipeline catalysts limits upside. The company faces competition from alternative cartilage repair treatments and burn care products. Overall, Vericel is a stable commercial entity with limited near-term innovation, warranting a moderate conviction score.

Upcoming Catalysts (preview)

• Q4 2026FDA label expansion for MACI to hip or ankle cartilage defects60% success
• Q2 2027FDA approval of NexoBrid for pediatric severe burns70% success
• Q3 2026Q3 2026 earnings report highlighting accelerated MACI sales growth80% success